Compare Inovio Pharmaceuticals Inc (INO) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $236.38 (market cap $44.37B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 497× Inovio Pharmaceuticals Inc's market cap, and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | TTWO | |
|---|---|---|
Market Cap | $89.27M | $44.37B |
Sector | Health | Media |
52-Week High | $2.87 | $262.29 |
52-Week Low | $1.05 | $189.69 |
Enterprise Value | $60.28M | $45.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Take-Two Interactive (TTWO) trades at $239.04, up 1.0% on the day, with a bullish technical outlook as the price approaches resistance near $240. The company reported three consecutive quarterly EPS beats but posted a net loss of -$4.48B in FY2025, with revenue growth to $5.63B. Investor focus remains on the upcoming Grand Theft Auto VI release, driving positive sentiment despite recent profitability challenges.
The stock offers significant upside to the consensus price target of $302.50, supported by strong analyst buy ratings (78.95%), but carries risks from high debt levels and negative margins. Near-term catalysts include Q2 2026 earnings on August 7, 2026, though execution on GTA VI and cost management are critical for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
